Syringe Driver Survey Database migration to MedicinesComplete - January 2023

Syringe Driver Survey Database has moved to MedicinesComplete and is no longer available on palliativedrugs.com.

It has been renamed to PCF’s Syringe Driver Database and is now accessed through Drug Compatibility Checker.

Drug Compatibility Checker, through MedicinesComplete is a new tool providing essential compatibility knowledge to support the administration of injectable drugs combining published data and clinical practice reports.

Find out more about Drug Compatibility Checker:https://about.medicinescomplete.com/publication/drug-compatibility-checker/

If you have a subscription to Palliative Care Formulary through MedicinesComplete, you will have access to PCF’s Syringe Driver Database through Drug Compatibility Checker, at no charge through 2023. 

To contribute to PCF’s Syringe Driver Database please continue to submit a clinical practice report using palliativedrugs.com here: https://www.palliativedrugs.com/syringe-driver-database.html

To learn more about a subscription to the Palliative Care Formulary through MedicinesComplete, please contact us here: https://info.medicinescomplete.com/sales

If you have any questions regarding access to PCF’s Syringe Driver Database or would like to renew your subscription to Palliative Care Formulary, please contact pharmpress-support@rpharms.com.

---

FDA approves 2mg naloxone nasal spray

29th December 2016

A 2mg naloxone nasal spray (Narcan; Adapt Pharma) has been approved in the USA. It is approved for use in opioid-dependent patients, expected to be at risk for severe opioid withdrawal, in situations where there is a low risk for accidental or intentional opioid exposure by household contacts.

A 4mg naloxone nasal spray (Narcan; Adapt Pharma) has been available since February 2016 (see our news item 26-11-2016).

The US Product Information for both the 2mg and 4mg naloxone nasal spray can be downloaded from here. 

click here to view